Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

David A. Sallman, MD, Hany Elmariah, MD MS, Kendra L. Sweet, MD MS, Chetasi Talati, MD, Asmita Mishra, MD, Linda L. Kelley, PhD, Amy Lankford, PhD, Tim Chan, PhD, Rutul R Shah, Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Helen Sabzevari, PhD, Marco L. Davila, MD PhD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-139417

Published: 2020

Journal Articles

Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

Ariel Perez Perez, MD, Christina A Bachmeier, PharmD, Renee Smilee, Albert J Ribickas, Aleksandr Lazaryan, MDPhDMPH, Julio C. Chavez, MD, Claudio Anasetti, MD, Bijal Shah, MD, Farhad Khimani, MBBS, Taiga Nishihori, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MDPhD, Hien D. Liu, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-143336

Published: 2020

Journal Articles

Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia

Justin C. Boucher, PhD, Bin Yu, Gongbo Li, PhD MBBS, Bishwas Shrestha, PhD, Jeffrey E. Lancet, MD, David A. Sallman, MD, Ana Marie Landin, Adam William Mailloux, PhD, Claudio Anasetti, MD, Linda L. Kelley, PhD, Marco L. Davila, MD PhD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136174

Published: 2020

Journal Articles

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139609

Published: 2020

Journal Articles

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Joseph Pidala, MD, Kelly Walton, Hany Elmariah, MDMS, Jongphil Kim, PhD, Asmita Mishra, MD, Nelli Bejanyan, MD, Taiga Nishihori, MD, Farhad Khimani, MBBS, Lia Perez, MD, Rawan Faramand, MD, Marco L. Davila, MD PhD, Michael Nieder, MD, Nicholas Lawrence, PhD, Harshani Lawrence, PhD, Claudio Anasetti, MD, Said Sebti, PhD, Brian C. Betts, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-133874

Published: 2020

Journal Articles

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma

Michael D. Jain, MD PhD, Hua Zhao, Reginald Atkins, Meghan A Menges, Crystal R Pope, Rawan Faramand, MD, Sae Bom Lee, Justin C. Boucher, PhD, Hiroshi Kotani, MD PhD, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Mohammad Hussaini, MD, Ricardo J Gonzalez, MD, John E Mullinax, MD PhD, Marco L. Davila, MD PhD, Frederick L. Locke, MD

Blood (2019) 134 (Supplement_1): 2885.

https://doi.org/10.1182/blood-2019-131041

Published: 2019

Journal Articles

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia

Bishwas Shrestha, PhD, Kelly Walton, Jordan Reff, Elizabeth M. Sagatys, MD, Nhan Tu, PhD, Justin C. Boucher, PhD, Tayyeb Ghafoor, BS, Joseph Pidala, MD, Bruce R. Blazar, MD, Claudio Anasetti, MD, Brian C. Betts, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 196.

https://doi.org/10.1182/blood-2019-124031

Published: 2019

Journal Articles

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

Michael D. Jain, MD PhD, Rawan Faramand, MD, Verena Staedtke, MD PhD, Renyuan Bai, MBBS, Sae Bom Lee, Hiroshi Kotani, MD PhD, Kayla Reid, Kristen Spitler, Julio Chavez, Bijal Shah, MD, Christina A Bachmeier, PharmD, Marian Dam, ARNP, Brigett Brandjes, PA, Ricardo J Gonzalez, MD, John E Mullinax, MD PhD, Xuefeng Wang, PhD, Mohammad Hussaini, MD, Frederick L. Locke, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 4105.

https://doi.org/10.1182/blood-2019-127305

Published: 2019

Journal Articles

MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption

Estelle V Cervantes, Justin C. Boucher, PhD, Sae Bom Lee, Kristen Spitler, Kayla Reid, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 4438.

https://doi.org/10.1182/blood-2019-122752

Published: 2019

Journal Articles

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Hamza Hashmi, MD, Alicia Darwin, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Javier Pinilla Ibarz, MD PhD, Taiga Nishihori, MD, Farhad Khimani, MD, Aleksandr Lazaryan, MDPhDMPH, Hien D. Liu, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 1612.

https://doi.org/10.1182/blood-2019-126148

Published: 2019

Journal Articles

Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function

Justin C. Boucher, PhD, Gongbo Li, PhD MBBS, Hiroshi Kotani, MD PhD, Maria Cabral, Dylan Morrissey, Sae Bom Lee, Kristen Spitler, Nolan Beatty, Bishwas Shrestha, PhD, Bin Yu, Aslamuzzaman Kazi, Xuefeng Wang, PhD, Said Sebti, PhD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 248.

https://doi.org/10.1182/blood-2019-122954

Published: 2019

Journal Articles

Aged CAR T Cells Exhibit Enhanced Cytotoxicity and Effector Function but Shorter Persistence and Less Memory-like Phenotypes

Hiroshi Kotani, MD PhD, Gongbo Li, PhD MBBS, Jiqiang Yao, PhD, Tania E. Mesa, BS, Jon Chen, PhD, Justin C. Boucher, PhD, Sean J. Yoder, MS, Jing Zhou, MD PhD, Marco L. Davila, MD PhD

Blood (2018) 132 (Supplement 1): 2047.

https://doi.org/10.1182/blood-2018-99-115351

Published: 2018

Journal Articles

Mutation of the CD28 Costimulatory Domain Confers Decreased CAR T Cell Exhaustion

Justin C. Boucher, PhD, Gongbo Li, PhD MBBS, Bishwas Shrestha, PhD BS, Maria Cabral, Dylan Morrissey, Lawrence Guan, Marco L. Davila, MD PhD

Blood (2018) 132 (Supplement 1): 966.

https://doi.org/10.1182/blood-2018-99-110645

Published: 2018

Journal Articles

Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel

Michael D. Jain, MD PhD, Julio C. Chavez, MD, Bijal D. Shah, MD, Farhad Khimani, MBBS, Aleksandr Lazaryan, MD PhD MPH, Marco L. Davila, MD PhD, Hien D. Liu, MD, Aaron D Falchook, MD, Timothy Robinson, MD, Sungjune Kim, MD PhD, Frederick L. Locke, MD

Blood (2018) 132 (Supplement 1): 4220.

https://doi.org/10.1182/blood-2018-99-117133

Published: 2018

Journal Articles

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1398.

https://doi.org/10.1182/blood-2018-99-114747

Published: 2018

Journal Articles

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

David A Sallman, MD, Tessa Kerre, MD, Xavier Poire, MD, Violaine Havelange, Philippe Lewalle, MD, Marco L. Davila, MD PhD, Eunice S. Wang, MD, Doreen Dekker, PhD, Sarah Snykers, PhD, Panagiota A. Sotiropoulou, PhD, Eytan Breman, Nathalie Braun, Caroline Lonez, PhD, Bikash Verma, MD DVM, Frédéric F. Lehmann, MD, Jason B. Brayer, PhDMD

Blood (2018) 132 (Supplement 1): 902.

https://doi.org/10.1182/blood-2018-99-111326

Published: 2018

Journal Articles

Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements

Rawan Faramand, MD, Hiroshi Kotani, MD PhD, Dylan Morrissey, Bin Yu, Frederick L. Locke, MD, Michael D. Jain, MDPhD, Julio C. Chavez, MD, Xuefeng Wang, PhD, Asmita Mishra, MD, Christina A Bachmeier, PharmD, Renier J. Brentjens, MD PhD, Sarah Yoo, Jae H. Park, MD, Marco L. Davila, MD PhD

Blood (2018) 132 (Supplement 1): 95.

https://doi.org/10.1182/blood-2018-99-116539

Published: 2018

Journal Articles

Next Generation Sequencing of Immunized Mouse Splenocytes to Develop an Anti-TIM3 Chimeric Antigen Receptor for Acute Myeloid Leukemia

Justin C. Boucher, PhD, Paresh Vishwasrao, Lawrence Guan, Bishwas Shrestha, PhD, Gongbo Li, PhD MBBS, Scott Christley, Lindsay G. Cowell, PhD, Jared Ostmeyer, William H. Rounds, Inimary T. Toby, PhD, Marco L. Davila, MD PhD

Blood (2017) 130 (Supplement 1): 2646.

https://doi.org/10.1182/blood.V130.Suppl_1.2646.2646

Published: 2017

Journal Articles

Mouse CD19-Targeted Chimeric Antigen Receptors That Include a 41BB Co-Stimulatory Domain Induce NFkB Signaling to Enhance T Cell Proliferation, Viability, and Leukemia Killing

Gongbo Li, PhD MBBS, Nolan Beatty, Paresh Vishwasrao, Justin C. Boucher, PhD, Bin Yu, Kyungho Park, Yongliang Zhang, PhD BMBS, Marco L. Davila, MD PhD

Blood (2017) 130 (Supplement 1): 843.

https://doi.org/10.1182/blood.V130.Suppl_1.843.843

Published: 2017

Journal Articles

CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL

Jae H Park, MD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Yvette J Bernal, MS, Sarah Yoo, Terrence Purdon, Elizabeth Halton, RN, MS, ANP, Hilda Quintanilla, RN, MS, ANP, Kevin J. Curran, MD, Craig S. Sauter, MD, Marco L Davila, MD PhD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2014) 124 (21): 382.

https://doi.org/10.1182/blood.V124.21.382.382

Published: 2014

NARROW

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function

Aged CAR T Cells Exhibit Enhanced Cytotoxicity and Effector Function but Shorter Persistence and Less Memory-like Phenotypes

Mutation of the CD28 Costimulatory Domain Confers Decreased CAR T Cell Exhaustion

Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements

Next Generation Sequencing of Immunized Mouse Splenocytes to Develop an Anti-TIM3 Chimeric Antigen Receptor for Acute Myeloid Leukemia

Mouse CD19-Targeted Chimeric Antigen Receptors That Include a 41BB Co-Stimulatory Domain Induce NFkB Signaling to Enhance T Cell Proliferation, Viability, and Leukemia Killing

CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only